

## CMS-1500 Sample Claim Form – BCBS of Kansas

**HEALTH INSURANCE CLAIM FORM**  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

**1. MEDICARE**  **MEDICAID**  **TRICARE**  **CHAMPVA**  **GROUP HEALTH PLAN**  **FECA BLK/LIING**  **OTHER**  **INSURED'S I.D. NUMBER** (For Program in Item 1)

**2. PATIENT'S NAME** (Last Name, First Name, Middle Initial) **3. PATIENT'S BIRTH DATE** MM DD YY **SEX** M  F

**4. INSURED'S NAME** (Last Name, First Name, Middle Initial)

**5. PATIENT'S ADDRESS** (No., Street) **6. PATIENT RELATIONSHIP TO INSURED** Self  Spouse  Child  Other

**7. INSURED'S ADDRESS** (No., Street)

**8. RESERVED FOR NUCC USE** **9. OTHER INSURED'S NAME** (Last Name, First Name, Middle Initial)

**10. IS PATIENT'S CONDITION RELATED TO:** a. EMPLOYMENT? (Current or Previous) YES  NO  b. AUTO ACCIDENT? YES  NO  c. OTHER ACCIDENT? YES  NO

**11. INSURED'S POLICY GROUP OR FECA NUMBER** **12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE** I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits due to myself or to the party who accepts assignment below.

**13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE** I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

**14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP)** MM DD YY **15. OTHER DATE** MM DD YY

**16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION** FROM MM DD YY TO MM DD YY

**17. NAME OF REFERRING PROVIDER OR OTHER SOURCE** **18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES** FROM MM DD YY TO MM DD YY

**19. ADDITIONAL CLAIM INFORMATION** (Designated by NUCC) **20. OUTSIDE LAB?** YES  NO

**21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY** Relate A-L to service line below (24E) **22. RESUBMISSION CODE** ORIGINAL REF. NO.

**23. PRIOR AUTHORIZATION NUMBER**

**24. A. DATE(S) OF SERVICE** From MM DD YY To MM DD YY **B. PLACE OF SERVICE** **C. EMG** **D. PROCEDURES, SERVICES, OR SUPPLIES** (Explain Unusual Circumstances) **E. DIAGNOSIS POINTER** **F. CHARGES** **G. DAYS** **H. EPSI** **I. ID. QUAL.** **J. RENDERING PROVIDER ID. #**

**25. FEDERAL TAX I.D. NUMBER** **SSN EIN** **26. PATIENT'S ACCOUNT NO.** **27. ACCEPT ASSIGNMENT?** YES  NO  **28. TOTAL CHARGE** \$ **29. AMOUNT PAID** \$ **30. Rsvd for NUCC Use**

**31. SIGNATURE OF PHYSICIAN OR SUPPLIER** INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) **32. SERVICE FACILITY LOCATION INFORMATION** **33. BILLING PROVIDER INFO & PH #** ( )

SIGNED DATE a. NPI b. NPI

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

**DISCLAIMER:** Claim completion requirements change very frequently; please check with your local plan to verify billing guidelines for each date of service.

**Item 21:**  
"ICD Ind" – Enter the applicable ICD indicator to identify which version of ICD codes is being reported.

*Example: 0 for ICD-10-CM codes*  
"Diagnosis Code" – Enter the appropriate diagnosis code.

*Example: G89.18 Other acute postprocedural pain*

**Item 19:**  
For NOC coded drugs, enter the description of the drug, NDC number and dosage administered.

*Example: ANJESO<sup>®</sup> 30 mg/mL, IV, NDC 71518-0001-01 MLI administered*

**Item 17a & b:**  
Enter appropriate NPI as assigned by CMS.  
*Note: See also Items 24, 32 and 33*

**Item 24A (shaded area):**  
Enter the product ID qualifier N4 followed by the 11-digit NDC, NDC description, the Unit of Measurement (UOM) identifier and the NDC quantity using a metric decimal quantity as administered to the member.

*Example: N471518000101 MLI*

**Item 24D: Product/Procedure Code(s)**  
**Product Code** – You may use C9059: Injection, meloxicam, 1 mg or J3490: Unclassified drugs.  
**Procedure Code(s)** – Enter the appropriate CPT code for the service provided or for the administration of the drug.

*Example: 96375 – Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug*

**Item 24G:**  
A unit of '1' must be entered for NOC coded drugs.

**Item 24F:**  
Medication Charge.

\*Provider: Please use the proper code depending on payer type.

**DISCLAIMER:** The details provided in this resource are for general reimbursement information only and are not legal advice nor are they advice about how to code, complete, or submit any particular claim for payment. Information provided is not intended to increase or maximize reimbursement by any payer. The information provided represents Baudax's understanding of current coverage and reimbursement policies as of April 1, 2020. It is a facility's and physician's responsibility to determine appropriate codes, charges, and modifiers, and submit bills for items and services consistent with the patient insurer requirements. Third-party payers may have different policies and coding requirements. Such policies can change over time. Baudax disclaims any responsibility for claims submitted by facilities or physicians. Providers should check and verify current policies and requirements with the payer for any particular patient.

Please see Important Safety Information on reverse and full Prescribing Information, including Boxed Warning, accompanying this resource and at [www.anjeso.com](http://www.anjeso.com).

## INDICATION

ANJESO is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.

Limitation of Use: Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required.

## IMPORTANT SAFETY INFORMATION

### WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

#### Cardiovascular Risk

- Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
- ANJESO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

#### Gastrointestinal Risk

- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

## CONTRAINDICATIONS

ANJESO is contraindicated in patients with:

- Known hypersensitivity (eg, anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product.
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
- In the setting of coronary artery bypass graft (CABG) surgery.
- Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion.

## WARNINGS AND PRECAUTIONS

**Hepatotoxicity:** Elevations of ALT or AST have been reported in patients with NSAIDs. In addition, rare, sometimes fatal, cases of severe hepatic injury including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue ANJESO immediately if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.

**Hypertension:** NSAIDs including ANJESO can lead to new onset of hypertension or worsening of preexisting hypertension, which may contribute to the increased incidence of cardiovascular (CV) events. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.

**Heart Failure and Edema:** NSAID use increased the risk of myocardial infarction (MI), hospitalization for heart failure, and death. Avoid use of ANJESO in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. If ANJESO is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

**Post MI Patients:** Avoid the use of ANJESO in patients with recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ANJESO is used in these patients, monitor for signs of cardiac ischemia.

**Renal Toxicity:** Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. ANJESO is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency who are at risk for renal failure due to volume depletion. Correct volume status in dehydrated or hypovolemic patients prior to initiating ANJESO. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ANJESO in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. If ANJESO is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

**Anaphylactic Reactions:** Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma. Seek emergency help if an anaphylactic reaction occurs.

**Exacerbation of Asthma Related to Aspirin Sensitivity:** ANJESO is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).

**Serious Skin Reactions:** NSAIDs, including ANJESO, can cause serious skin reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and can occur without warning. Discontinue ANJESO at first appearance of skin rash or other signs of hypersensitivity.

**Hematologic Toxicity:** Anemia has occurred in NSAID-treated patients. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. NSAIDs, including ANJESO, may increase the risk of bleeding events. Monitor patients for signs of bleeding.

## DRUG INTERACTIONS

**Drugs That Interfere With Hemostasis (eg, warfarin, aspirin, SSRIs/SNRIs):** Monitor patients for bleeding who are concomitantly taking ANJESO with drugs that interfere with hemostasis. Concomitant use of ANJESO and analgesic doses of aspirin is not generally recommended.

**Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers:** Concomitant use with ANJESO may diminish the antihypertensive effect of these drugs. Monitor blood pressure.

**ACE Inhibitors and ARBs:** Concomitant use with ANJESO in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function.

**Diuretics:** NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to ensure diuretic efficacy including antihypertensive effects.

## ADVERSE REACTIONS

The most common adverse reactions in controlled clinical trials occurring in  $\geq 2\%$  of patients treated with ANJESO and at a greater frequency than placebo include: constipation, gamma-glutamyl transferase increased, and anemia.

## USE IN SPECIFIC POPULATIONS

**Pregnancy:** Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus.

Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation.

**Infertility:** NSAIDs are associated with reversible infertility. Consider withdrawal of ANJESO in women who have trouble conceiving.

**Please see full Prescribing Information, including Boxed Warning, accompanying this resource and at [www.anjeso.com](http://www.anjeso.com).**

**Baudax BIO**

0220-055.b

Copyright © 2020 Baudax Bio, Inc. All rights reserved.  
ANJESO is a registered trademark of Baudax Bio, Inc.